ArticleJournal of veterinary science2026
Catecholamine-associated left ventricular hypertrophy in dogs with hyperadrenocorticism and myxomatous mitral valve disease: a prospective pilot study.
Article in Journal of veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceEndogenous Cushing's syndrome increases the risk of cardiac hypertrophy, dysfunction, and cardiovascular mortality. Given the high prevalence of hyperadrenocorticism (HAC) and myxomatous mitral valve disease (MMVD) in dogs, endocrine-cardiac interactions may influence disease progression but remain poorly characterized.
objectiveTo evaluate the effects of concurrent HAC on cardiac remodeling and function in dogs with subclinical MMVD and identify metabolic and neurohormonal markers, particularly catecholamine metabolites, associated with left ventricular hypertrophy and dysfunction.
methodsTwenty-one client-owned dogs (HAC + MMVD, MMVD-only controls, and healthy controls [each n = 7]) were prospectively enrolled. Echocardiographic variables, including speckle-tracking echocardiography, hematologic and biochemical parameters, and urinary normetanephrine: creatinine ratios, were evaluated at baseline and follow-up.
resultsThe HAC + MMVD group showed significantly increased urinary normetanephrine: creatinine ratios than both healthy control group and MMVD-only control group ( CONCLUSIONS AND RELEVANCE: This exploratory pilot study is the first suggesting a potential neuroendocrine mechanism underlying endocrine-cardiac remodeling in dogs with concurrent HAC and MMVD, whereby increased catecholamine activity may be associated with left ventricular hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.